A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)

I put this slightly below even odds. The study is randomized, placebo-controlled, and uses a direct lesion-count endpoint at Week 16, which should be sensitive to drug effect and easier to power than a harder long-term outcome. Moderate to severe HS gives room for separation from placebo if the mechanism is active. That said, HS studies are noisy: lesion counts fluctuate, placebo responses can be meaningful, and disease burden is heterogeneous across patients. The primary endpoint is clinically relevant, but it is less standard than responder-style HS endpoints, so even a statistically positive result may be less robust than it first appears. As a Phase 2 trial, dose selection, effect-size uncertainty, and limited visible prior HS efficacy support add risk. Operationally, the trial is just past primary completion, but the still-active status leaves some disclosure ambiguity rather than increasing confidence. Overall, the design is credible, yet biology and execution risk keep YES modestly below 50%.

Brensocatib's CEDAR trial in HS faces significant headwinds. The BiRCh study (same drug, same doses, same Phase 2b design) completely failed in CRSsNP in Dec 2025, missing all primary and secondary endpoints. While HS has stronger neutrophil/NE mechanistic rationale than CRSsNP—with clear neutrophil elastase elevation in HS lesions—the BiRCh failure demonstrates brensocatib's DPP1 inhibition does not reliably translate across neutrophil-mediated diseases beyond bronchiectasis. The CEDAR trial is adequately powered (~214 pts) with a well-validated AN count endpoint, and the trial was designed rigorously (quadruple-blind, placebo-controlled). However, HS is multifactorial with IL-17, TNF-α, and neutrophil pathways all contributing, so targeting NSPs alone may be insufficient. Base rate for Phase 2 dermatology success is ~30-35%. The futility analysis (planned Q1 2026) apparently did not trigger early termination, which is mildly positive, but not conclusive. No topline results disclosed yet. Overall probability of positive results estimated at 35%.

Brensocatib is a DPP-1 inhibitor being evaluated in Phase 2 for HS, a chronic inflammatory skin disease with significant unmet need. The primary endpoint measures percent change in AN count at Week 16, which is clinically meaningful. Insmed has prior experience with this compound in bronchiectasis trials. However, Phase 2 trials carry inherent uncertainty with typical success rates around 30-40%, and HS is a notoriously difficult indication with complex pathophysiology. The trial has passed its primary completion date (-49 days), suggesting data may be maturing. Given the early phase, novel mechanism, and challenging disease target, I assign modest probability of positive outcome, below even odds. Market pricing at ~49.5% appears roughly aligned but slightly optimistic given Phase 2 risks.

This Phase 2 trial for brensocatib in hidradenitis suppurativa (HS) has high uncertainty. The primary endpoint, percent change in abscess and nodule count, is a standard and objective measure. However, brensocatib is a DPP1 inhibitor, a novel mechanism for HS, with limited prior efficacy data in this specific inflammatory condition. The patient population (moderate to severe HS) is challenging with high placebo response rates historically. While the trial is 'Active Not Recruiting' and the primary completion date has passed, results are not yet disclosed, creating binary event risk. The sponsor, Insmed, has experience, but the intrinsic probability hinges on unproven biology in HS, leading to a cautious estimate below 50%.

Phase 2 placebo-controlled trial of brensocatib (DPP1 inhibitor) in moderate-severe HS uses standard, reliable primary endpoint: % change in total AN count at Week 16. Design solid, population appropriate for HS (neutrophilic/inflammatory disease). Sponsor Insmed has strong execution history, positive prior brensocatib Phase 2 in bronchiectasis (similar inflammation). HS has unmet need but Phase 2 hit rate ~35-45% for novel MOAs; biologics succeed more than small molecules. No enrollment size, stratification, or HS-specific priors given, adding uncertainty. Endpoint sensitive, historical placebo responses ~ -20-30%, drug needs >40% for significance. Operational risks low. Primary completion 49 days past (Feb 2026), high disclosure risk but no leaks implies no blowout positive. Intrinsic YES ~42%: plausible efficacy signal but unproven in HS.

Brensocatib is a highly selective oral DPP1 inhibitor with a novel mechanism targeting neutrophil-driven inflammation, which is central to Hidradenitis Suppurativa (HS) pathophysiology. The drug has already demonstrated robust efficacy in a Phase 2b study for Bronchiectasis, significantly reducing neutrophil elastase activity, suggesting strong translational potential for HS. This Phase 2 trial design uses a validated primary endpoint: percent change in total abscess and inflammatory nodule (AN) count at Week 16. This endpoint is clinically meaningful and aligns with FDA precedents. The trial status is 'Active Not Recruiting' with primary completion estimated for February 2026, indicating the study is fully enrolled and data collection is mature. Given the established biological rationale, prior mechanistic validation in other neutrophilic diseases, and a standard endpoint, the probability of a statistically significant positive result is favorable. The primary risk remains the specific effect size in a new indication, but the mechanistic hypothesis is strong.

Brensocatib is a DPP1 inhibitor with mixed prior HS data. The Phase 2 SOLSTICE trial in non-CF bronchiectasis showed efficacy, but HS is a different inflammatory pathway with high placebo response rates historically (30-40%). The primary endpoint is percent change in AN count at Week 16—a validated but noisy endpoint in HS where lesion counting has inter-rater variability. The trial completed enrollment 49 days ago, suggesting data may be imminent, increasing disclosure risk. No interim efficacy data has been announced, which is concerning given Insmed's tendency to disclose positive signals early. The placebo-controlled design is appropriate, but HS Phase 2 trials have high failure rates. Moderate sample size typical for Phase 2 HS studies. No biomarker enrichment strategy limits precision. Brensocatib's mechanism is rational but unproven in HS specifically.

Brensocatib is an oral DPP1 inhibitor targeting neutrophil serine proteases (NSPs). While successfully approved for bronchiectasis, its broader utility in inflammatory diseases was dealt a major blow with the Phase 2b failure in CRSsNP in December 2025. Hidradenitis suppurativa (HS) is notoriously recalcitrant, characterized by high placebo response rates and a high failure rate for novel mechanisms. Validated targets in HS are primarily upstream cytokines (TNF-alpha, IL-17); targeting downstream NSPs may not adequately resolve the inflammatory nodules and abscesses. The Phase 2 CEDAR trial employs a continuous primary endpoint (percent change in total AN count), which offers a marginally lower statistical hurdle than the standard binary HiSCR50 responder analysis. Additionally, Insmed implicitly passed the planned Q1 2026 interim futility analysis, as management continues to guide for a Q2 2026 topline readout. However, futility hurdles are typically very low. These mitigating factors do not fully offset the biologic risk exposed by the CRSsNP failure and the historical difficulty of achieving proof-of-concept in HS. The intrinsic probability of a positive result is approximately 35%, significantly below current market pricing.

The trial is in Phase 2, which is a relatively early stage but still informative. The primary endpoint is a clear and measurable outcome (percent change from baseline in total abscess and inflammatory nodule count). The study has a control arm (placebo) and an intervention arm (brensocatib), allowing for a direct comparison. Given that the trial is active but not recruiting, it is likely that the data is being analyzed or is close to completion. The sponsor, Insmed Incorporated, has a vested interest in a positive outcome. However, without specific data on the patient population, dosing, and prior results, the forecast leans on general trial design strengths.